📈Three-dimensional cutting guides, robotic-guided surgery, near-infrared imaging, and AI-driven workflows may revolutionize sarcoma surgical management, according to @RLRandallMD, of @UCD_Cancer. Read on for more insights ➡️: onclive.com/view/novel-preci…

🗣️"The next phase [of research in TGCT] is not simply finding another drug that shrinks the tumor; it's determining which intervention provide the best long-term function and QOL for each individual patient," said @RLRandallMD of @UCD_Cancer on what’s next for TGCT treatments. Read more ➡️: onclive.com/view/systemic-th… #oncology #scmsm

@RLRandallMD of @UCD_Cancer reviews a longitudinal study in osteosarcoma showing a strong correlation between ctDNA status and clinical outcomes like EFS. #oncology #medtwitter #sarcoma hubs.li/Q04mQFL90

⚛️ “We are moving toward a model where tumor biology informs not only survival but how well patients function, and that is a meaningful evolution for our field,” said @RLRandallMD of @UCD_Cancer on the introduction of systemic therapies like pimicotinib in TGCT enables a tumor biology–informed approach to care. Read more here 📰: hubs.li/Q04hKmHc0 #oncology

WATCH 👀: @RLRandallMD of @UCDavisHealth discusses the rationale of a meta-analysis comparing IM nailing and EP reconstruction for patients with bone metastases. See the whole video here ➡️: hubs.li/Q04f4hjb0 #oncology

⚛️ "IM nailing can be advantageous early; if the prognosis for a patient is particularly grim," said @RLRandallMD of @UCDavisHealth on a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases. Full details 📰: hubs.li/Q04dtWgw0 #oncology

.@RLRandallMD, highlights a recent meta-analysis comparing 2 approaches to surgical management for patients with femoral metastases. @UCD_Cancer #scmsm #oncology onclive.com/view/im-nailing-…

⚛️ “This consensus provides much-needed initial clarity for the day-to-day management of PJIs in patients [with sarcoma] but also underscores how much work remains to elevate the evidence base,” said @RLRandallMD of @ucdavis on key takeaways from the BOOM consensus meeting on PJI management in orthopedic oncology. Read more here 📈: hubs.li/Q049NCYq0 #oncology

How should periprosthetic joint infections be managed in orthopedic oncology when high-level evidence is limited? In this clip, @RLRandallMD of @UCD_Cancer discusses the clinical impetus for the Birmingham Orthopedic Oncology Meeting (BOOM) initiative and the rationale for using a modified Delphi consensus approach in the setting of limited high-level evidence. ▶️ Watch this short and read the full Q&A for key takeaways from the BOOM report:🔗 hubs.li/Q048GXl20 #BoomConsensus #BOOM2026 #BJJ #orthopediconcology

WATCH 📺: @RLRandallMD of @UCDavisHealth outlines key clinical and treatment variables associated with local recurrence risk in patients with nonmetastatic Ewing sarcoma treated with interval compression therapy. 📊 Delve into findings from this contemporary analysis by watching the video below! 👇 #sarcsm #oncology onclive.com/view/dr-randall-…

👀“The take-home message in this modern multi-modality therapy study is that future efforts should focus on identifying and intensifying treatment for the high-risk subsets," said @RLRandallMD of @UCD_Cancer on a local therapy modality analysis in nonmetastatic ewing sarcoma. Read more here ➡️: hubs.li/Q044LW4p0 #oncology

Diffuse #TGCT remains a challenge, but targeted therapies offer new hope. Discover expert strategies for integrating CSF1R inhibitors into personalized care plans. Drs. @WTapMD & @RLRandallMD discuss clinical data and patient cases at #CTOS2025 #MedEd 📺 Participate now: bit.ly/3IpZHxa

🌎 "Standardization is essential. Without unified definitions, multicenter trials and meta-analyses are impossible," said @RLRandallMD of @UCD_Cancer, on the need for standard DAIR terminology. Read more here 📰: hubs.li/Q03-dZ390 #oncology